Liraglutide: a once-daily human glucagon-like peptide-1 analogue.
Aimaretti
G
G
Endocrinology, Department of Experimental and Clinical Medicine, University A. Avogadro del Piemonte Orientale, 28100 Novara, Italy. gianluca.aimaretti@med.unipmn.it
D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D003924:Diabetes Mellitus, Type 2 / Q000178:diet therapy / Q000503:physiopathology; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D050417:Insulin-Secreting Cells / Q000187:drug effects / Q000502:physiology; D000069450:Liraglutide
D007004:Hypoglycemic Agents; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1